Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
U1 small nuclear RNA 2 (RNU1-2) is a noncoding RNA that serves as a key component of the U1 small nuclear ribonucleoprotein (snRNP) complex, which initiates spliceosome-mediated removal of introns from pre-mRNA transcripts, a critical process for generating mature messenger RNA in eukaryotic cells[1][2][3][4]. RNU1-2 forms the RNA backbone of the U1 snRNP through protein-RNA interactions and base pairing with the 5′ splice site of pre-mRNA, ensuring accurate splicing. It is not considered a traditional therapeutic target (e.g., not a receptor, enzyme, transporter) but is essential for basic cell function and is sometimes used as a stable reference gene in molecular biology assays relating to gene expression and cancer biomarker discovery[1]. Errors in its function or processing can contribute to the splicing defects observed in many diseases, including cancers and certain genetic disorders[2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on U1 small nuclear RNA 2 (RNU1-2).